Clinical Analysis Of Gemcitabine-Platinum Combinations In Patients With Advanced Non-Small-Cell Lung Cancer

Objective: To evaluate the efficacy and toxicity of gemcitabine-platinum combinations in patients with advanced non-small-cell lung cancer (NSCLC).Methods: 45 patients (chemotherapy-niave and pre-treated cases 35 and 10 respectively) with cytologically or histologically proven stage IIIb~IV NSCLC received gemcitabine-platinum (cisplatin, carboplatin, or oxaliplatin) combinations. Each regimen was repeated every 3 weeks. Efficacy was assessed for patients received at least 2 cycles of chemotherapy.Results: A total of 158 cycles were completed, all patients were available for evaluating response and toxicity. Response rate (RR, CR+PR) of gemcitabine/cisplatin, gemcitabine/carboplatin and gemcitabine/oxaliplatin was 47.4%(9/19), 45.5%(5/11) and 40.0%(6/15) respectively, the overall RR was 44.4%(20/45). The median survival time was 8.9 months, and the 1 year survival rate was 38.7%. The major toxicities included hematological toxicity, gastrointestinal reactions, skin rash and pruritus.Conclusion: Gemcitabine-platinum combinations are valuatble and well tolerated in patients with advanced NSCLC, these regimens can be recommended for more use in the future.